MacuSight Receives Fast Track Designation From FDA for Perceiva inTreatment of Diabetic Macular Edema

Wed, 10/21/2009 - 4:53am
MacuSight, a developer ofinnovative therapeutics for the treatment of severe ocular diseases andconditions, today announced that it has received Fast Track designation fromthe United States Food and Drug Administration (FDA) for Perceiva, thecompany's proprietary ocular sirolimus product, for the treatment of diabeticmacular edema (DME). MacuSight is currently advancing Perceiva in a broadPhase 2 clinical program across multiple large ocular indications. Thecompany recently announced that it had completed enrollment in four separatePhase 2 studies which are evaluating Perceiva as a treatment for DME,neovascular (wet) age-related macular degeneration (wet AMD) and dry eyesyndrome. The company plans to announce data from these studies in the firsthalf of 2010.

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.